Micron Technology, Inc. (MU.US) sparks heated debate over growth prospects after breaking trillion-dollar market value.
Micron Technology joins trillion-dollar market value club, market long and short disagreements intensify: Institutions are optimistic about profit and valuation reassessment supported by AI storage demand, while also cautious of overvaluation pricing, cycle reversal, and profit margin decline risks.
Last Tuesday, Micron Technology, Inc. (MU.US) joined the ranks of American trillion-dollar companies, but at the same time, there were also some bearish voices in the market. Despite the stock price increasing more than tenfold in the past 12 months, Wall Street overall still maintains a slightly optimistic attitude towards it.
Various perspectives
"Benefiting from the explosive growth in revenue and profit margins driven by AI data center demand, Micron Technology, Inc.'s stock price has increased nearly 700% over the past year," analyst Kenio Fontes wrote. "The short-term upward momentum is expected to continue, but risk management is crucial considering the potential for a sharp correction due to operational leverage reversal."
"I believe Micron Technology, Inc. still has about 50% upside potential in the next 12-24 months, with the main risk being potential demand stagnation and rapid storage price corrections," added Danil Sereda, head of Investing Group. "The industry's tight supply situation is expected to continue at least until 2028, supporting high DRAM/HBM prices and driving the company to achieve extremely strong profit margins and free cash flow."
"There is no denying that Micron Technology, Inc.'s impressive gains are significantly increasing the stock's sensitivity to news event risks, especially those related to the sustainability of storage demand and prices," Summit Research pointed out. "With yield improvements and a transition to long-term strategic customer agreements (SCA), Micron Technology, Inc. still has conditions for continuously thickening free cash flow, and there is still further upside potential in the current stock price."
"Micron Technology, Inc. is transitioning from a cyclical storage supplier to a strategic AI infrastructure enabler, which brings opportunities for revaluation," added Agar Capital. "I give Micron Technology, Inc. a 'strong buy' rating with a target price of $1,000, based on strong AI-driven demand, sustainable profit levels, and despite the recent sharp increase in stock price, its dynamic P/E ratio is still below 8 times, giving it a valuation advantage."
"With the tight supply situation expected to continue beyond 2026, Micron Technology, Inc. has given guidance for Q3 revenue of approximately $33.5 billion and a gross margin of 81%," Quantryon Capital stated. "Although the company has already achieved structural improvements in profit margins, has long-term large-scale customer agreements, and benefits from AI scarcity economics, its current dynamic P/E ratio is only about 15.3 times."
Bearish perspective
"Micron Technology, Inc. joining the trillion-dollar market cap club is mainly driven by UBS Group AG tripling its target price, with little other new fundamental support," Tech Stock Pros stated bluntly. "We expect Micron Technology, Inc.'s Q3 earnings report (especially profit margin data) to provide a reality check to the market, and it will only show attractive investment value after the market expects a correction."
"The current stock price fully reflects the continued state of supply and demand imbalance and leaves no safety margin for performance in 2027," added Exseleryn Analytics. "We are downgrading Micron Technology, Inc. to 'hold' because its overtrillion-dollar market cap has priced in a permanent AI super cycle, overlooking the imminent 2027 profit margin risks."
Related Articles

Subsidiary of Hunan Dajiaweikang Pharmaceutical Industry (301126.SZ) receives azithromycin dry powder for oral suspension drug registration certificate.

ANDRE JUICE (02218): In May, a total of 3.3075 million H shares were repurchased.
Citic Lyon: Initiate coverage on DPC DASH (01405) with "outperform" rating, target price of HKD 49.
Subsidiary of Hunan Dajiaweikang Pharmaceutical Industry (301126.SZ) receives azithromycin dry powder for oral suspension drug registration certificate.

ANDRE JUICE (02218): In May, a total of 3.3075 million H shares were repurchased.

Citic Lyon: Initiate coverage on DPC DASH (01405) with "outperform" rating, target price of HKD 49.





